Clinical Trials Logo

Filter by:
NCT ID: NCT05221840 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

PACIFIC-9
Start date: February 7, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.

NCT ID: NCT05220007 Completed - Glaucoma Clinical Trials

Effect of Presbyopic Correction Lens on Humphrey Visual Field Testing in Patients With Multifocal Intraocular Lens

Start date: June 1, 2009
Phase: N/A
Study type: Interventional

Purpose of this study was to evaluate the effect of presbyopic correction lens on Humphrey visual field (HVF) testing in patients with 2 models of multifocal intraocular lens (MIOL) both with and without glaucoma. All participants performed HVF testing with presbyopic collection lenses and without presbyopic collection lenses on the same occasion (5-10 minutes between the test). The mean deviation (MD) and pattern standard deviation (PSD) were compared between with and without presbyopic collection lenses, between glaucoma and non-glaucoma and between 2 models of MIOL.

NCT ID: NCT05219747 Not yet recruiting - Oral Mucosa Clinical Trials

The Effectiveness and Safety of Mucoadhesive Film Containing A.Oleracea Extract

Start date: February 28, 2022
Phase: N/A
Study type: Interventional

Several natural products have been use to promote wound healing and relieve pain. Acmella oleracea has a component that has anesthetic and anti-inflammatory properties. The mucoadhesive film can be improved by drug delivery system due to close contact with the absorption tissue leading to improvement in both local and systemic effects. This study aims to evaluate the effectiveness and safety of mucoadhesive film containing Acmella oleracea extract in healthy subjects. This is a randomised, double-blind (participant and investigator), parallel-controlled clinical trial. In total, approximately 72 subjects will be enrolled into study. Objectives 1. To investigate the potential of skin allergy reaction to mucoadhesive film containing Acmella oleracea extract in healthy subjects 2. To study the duration of mucosal adhesion of mucoadhesive film 3. To study the local anesthetic effect, participant's satisfaction and adverse effect of mucoadhesive film containing Acmella oleracea extract

NCT ID: NCT05217407 Recruiting - Clinical trials for Rare Malignant Neoplasm

Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia

MASTERKEY ASIA
Start date: November 30, 2021
Phase:
Study type: Observational [Patient Registry]

This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing. The relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.

NCT ID: NCT05215990 Recruiting - Clinical trials for Tuberculosis, Pulmonary

Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis

Start date: January 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study was a randomized controlled trial studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients between metformin with pulmonary tuberculosis standard treatment group and placebo drug with pulmonary tuberculosis standard treatment.

NCT ID: NCT05215340 Recruiting - Clinical trials for Metastatic Non Small Cell Lung Cancer

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

TROPION-Lung08
Start date: March 4, 2022
Phase: Phase 3
Study type: Interventional

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

NCT ID: NCT05203900 Completed - Clinical trials for Low Birth Weight Infants

The Influence by Dietary Human Milk Oligosaccharide in Low Birth Weight Infants

Start date: December 13, 2021
Phase: N/A
Study type: Interventional

This study aims to investigate the concentration of various growth factors and cytokines in blood, and to examine the gut microbiota of low birth weight infants fed with formulas with or without Human Milk Oligosaccharide (HMO) supplement. Eligible low birth weight infants are allocated to two groups, Investigational formula (with HMO) or Control formula (without HMO). The subjects are taking the assigned formula when they need to be supplemented with formula. After the informed consent was obtained and eligibility was confirmed, the intervention period begins, and ends at the one-month-old medical check-up with the assessment of the various blood growth factors and cytokines, and the gut microbiota.

NCT ID: NCT05201794 Recruiting - Dengue Clinical Trials

A Study of JNJ-64281802 for the Prevention of Dengue Infection

Start date: February 22, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to the last day of dosing among participants who have no evidence of current DENV infection at baseline.

NCT ID: NCT05198596 Completed - COVID-19 Vaccine Clinical Trials

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

Start date: July 30, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the immunogenicity and safety of MVC- COV1901 vaccine compared to AZD1222 in heathy adults.

NCT ID: NCT05197712 Active, not recruiting - COVID-19 Vaccine Clinical Trials

Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease

Start date: March 28, 2022
Phase: Phase 1
Study type: Interventional

The investigational product Baiya SARS-CoV-2 Vax 2 vaccine is a second-generation of protein subunit vaccine from plant. The primary objective aiming to evaluate the safety, tolerability, and reactogenicity of Baiya SARS-CoV-2 Vax 2 in adults (aged between 18 to 64 years, inclusive) after 2 doses of Baiya SARS-CoV-2 Vax 2 given 21 days apart IM, up to 28 days after the second vaccination. The secondary objective aiming to evaluate long-term safety profile (up to 1 year) and evaluate immunogenicity after 2 doses of Baiya SARS-CoV-2 Vax 2 given 21 days apart.